Sugi Predict

Sugi Predict / Compounds / Aficamten

Aficamten

Aficamten

SCHEMBL21179170

CCc1nc(-c2ccc3c(c2)CC[C@H]3NC(=O)c2cnn(C)c2)no1

nearest known ligand 0.44

Full drug profile on Sugi Atlas →

Predicted protein targets (top 14)

geneUniProtsupporting neighboursconfidence
▸ BTK Q06187 13/20 0.44
▸ CD69 Q07108 6/20 0.43
▸ CYP2C9 P11712 3/20 0.43
▸ CYP3A4 P08684 2/20 0.43
▸ WDR5 P61964 1/20 0.42
▸ KCNH2 Q12809 1/20 0.42
▸ ALDH1A1 P00352 1/20 0.42
▸ TSHR P16473 1/20 0.42
▸ HTT P42858 1/20 0.42
▸ NPSR1 Q6W5P4 1/20 0.42
▸ LIPG Q9Y5X9 1/20 0.41
▸ SMPD1 P17405 1/20 0.41
▸ KLKB1 P03952 1/20 0.40
▸ BDKRB1 P46663 1/20 0.39

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
Aficamten SCHEMBL21179172 1.00 BTK (0.44) BTKCD69CYP2C9CYP3A4WDR5
Aficamten SCHEMBL30167980 1.00 BTK (0.44) BTKCD69CYP2C9CYP3A4WDR5
SCHEMBL21178599 0.95 ALDH1A1 (0.48) BTKCD69CYP2C9CYP3A4KCNH2
SCHEMBL21178675 0.95 ALDH1A1 (0.48) BTKCD69CYP2C9CYP3A4KCNH2
SCHEMBL21270716 0.95 ALDH1A1 (0.48) BTKCD69CYP2C9CYP3A4KCNH2
SCHEMBL30008607 0.91 ALDH1A1 (0.46) BTKCD69CYP2C9CYP3A4WDR5
SCHEMBL21270515 0.91 ALDH1A1 (0.46) BTKCD69CYP2C9CYP3A4WDR5
SCHEMBL21178517 0.91 KLKB1 (0.43) BTKALDH1A1TSHRHTTNPSR1
SCHEMBL21178519 0.91 KLKB1 (0.43) BTKALDH1A1TSHRHTTNPSR1
SCHEMBL21270357 0.90 WDR5 (0.42) BTKCD69CYP2C9CYP3A4WDR5

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 102 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
CN-119119018-A Polymorphs 赛特凯恩蒂克公司 2024-12-13 — — CN claimed
CN-118908951-A Polymorphs 赛特凯恩蒂克公司 2024-11-08 — — CN claimed
EP-3740481-B9 DIHYDROBENZOFURAN AND INDEN ANALOGS AS CARDIAC SARCOMERE INHIBITORS CYTOKINETICS INC (US) 2024-10-23 — — EP claimed
CN-114555590-B Polymorphs of (R) -N- (5- (5-ethyl-1, 2, 4-oxadiazol-3-yl) -2, 3-dihydro-1H-inden-1-yl) -1-methyl-1H-pyrazole-4-carboxamide 赛特凯恩蒂克公司 2024-09-10 — — CN claimed
EP-3740481-B1 DIHYDROBENZOFURAN AND INDEN ANALOGS AS CARDIAC SARCOMERE INHIBITORS CYTOKINETICS INC (US) 2024-06-26 — — EP claimed
EP-3999180-B1 POLYMORPHS OF (R)-N-(5-(5-ETHYL-1,2,4-OXADIAZOL-3-YL)-2,3-DIHYDRO-1H-INDEN-1-YL)-1-METHYL-1H-PYRAZOLE-4-CARBOXAMIDE CYTOKINETICS INC (US) 2024-05-08 — — EP claimed
EP-3999038-B1 CARDIAC SARCOMERE INHIBITOR ORAL FORMULATIONS CYTOKINETICS INC (US) 2024-01-10 — — EP claimed
CN-114765954-B Oral preparation of cardiac sarcomere inhibitor 赛特凯恩蒂克公司 2024-01-02 — — CN claimed
US-20220315571-A1 POLYMORPHS OF (R)-N-(5-(5-ETHYL-1,2,4-OXADIAZOL-3-YL)-2,3-DIHYDRO-1H-INDEN-1-YL)-1-METHYL-1H-PYRAZOLE-4-CARBOXAMIDE CYTOKINETICS, INC. 2022-10-06 — — US claimed
US-20220265612-A1 CARDIAC SARCOMERE INHIBITOR ORAL FORMULATIONS CYTOKINETICS, INC. 2022-08-25 — — US claimed
CN-114765954-A Oral preparation of cardiac sarcomere inhibitor 赛特凯恩蒂克公司 2022-07-19 — — CN claimed
CN-114555590-A Polymorphs of (R) -N- (5- (5-ethyl-1, 2, 4-oxadiazol-3-yl) -2, 3-dihydro-1H-inden-1-yl) -1-methyl-1H-pyrazole-4-carboxamide 赛特凯恩蒂克公司 2022-05-27 — — CN claimed
US-10836755-B2 Cardiac sarcomere inhibitors CYTOKINETICS, INC. (US) 2020-11-17 — — US claimed
US-20260097021-A1 METHODS FOR TREATING HYPERTROPHIC CARDIOMYOPATHY CYTOKINETICS INC (US) 2026-04-09 — — US disclosed
US-20250382286-A1 CO-CRYSTAL OF AFICAMTEN, AND PREPARATION METHOD THEREFOR AND USE THEREOF CRYSTAL PHARMACEUTICAL (SUZHOU) CO., LTD. (CN) 2025-12-18 — — US disclosed
EP-4380932-B1 PROCESS FOR PREPARING AFICAMTEN CYTOKINETICS INC (US) 2025-11-26 — — EP disclosed
CN-111757875-A Dihydrobenzofuran and indene analogs as inotropic agents 赛特凯恩蒂克公司 2020-10-09 — — CN disclosed
US-20190256504-A1 CARDIAC SARCOMERE INHIBITORS CYTOKINETICS, INC. 2019-08-22 — — US disclosed
US-20190256504-A1 CARDIAC SARCOMERE INHIBITORS CYTOKINETICS, INC. 2019-08-22 — — US disclosed
WO-2019144041-A1 DIHYDROBENZOFURAN AND INDEN ANALOGS AS CARDIAC SARCOMERE INHIBITORS CYTOKINETICS, INC. (US) 2019-07-25 — — WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20220265612-A1 CARDIAC SARCOMERE INHIBITOR ORAL FORMULATIONS TNNI3, TNNT2, TNNC1 BTK 3246/4885CD69 4883/4885CYP2C9 3105/4885
US-10836755-B2 Cardiac sarcomere inhibitors TNNI3, TNNT2, MYLK2 BTK 2996/4885CD69 4869/4885CYP2C9 3489/4885
US-20260097021-A1 METHODS FOR TREATING HYPERTROPHIC CARDIOMYOPATHY TNNT2, TNNC1, MYH2 BTK 4484/4885CD69 1538/4885CYP2C9 1617/4885
US-20190256504-A1 CARDIAC SARCOMERE INHIBITORS TNNI3, TNNT2, MYLK2 BTK 2996/4885CD69 4869/4885CYP2C9 3489/4885
US-20220315571-A1 POLYMORPHS OF (R)-N-(5-(5-ETHYL-1,2,4-OXADIAZOL-3-YL)-2,3-DIHYDRO-1H-INDEN-1-YL)-1-METHYL-1H-PYRAZOLE-4-CARBOXAMIDE CYP2E1, CYP3A4, COX4I1 BTK 4703/4885CD69 4838/4885CYP2C9 91/4885
US-20250382286-A1 CO-CRYSTAL OF AFICAMTEN, AND PREPARATION METHOD THEREFOR AND USE THEREOF TNNT2, TNNC1, MYLK2 BTK 4542/4885CD69 3125/4885CYP2C9 1164/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.

Send feedback